This Is MS Multiple Sclerosis Knowledge & Support Community

Dr. Dake is obviously training at least one other doctor at Stanford, Dr. Forrester. I watched him do my procedure with Dake in the background guiding. I really liked Forrester, looks you in the eye, not rushed, compassionate. He said he had done about 20 procedures with Dake, although I don't know if I was the first he did by himself?? Does anyone else remember Forrester?

I do, and oddlty I recall so many things avout that surgery even though I was feeling no pain!
Forrester came with Dake on his rounds the morning after surgery, but I do not know if he was in O.R. the night before, though I assume so. Daisyduck

Daisyduck,

I was wondering how you were doing these days. Since you were one of the first to have the stents, I was hoping that you were doing better. Sounds like you are. Maybe you can update us or enter your info in the Tracking Stickey for all to read. Thanks.

I stumbled over this on the internet and it's dated 4/28/09. This is pretty interesting reading. Seems we MS's are really big business and predicted to become even bigger business over the next 15 years!
Now that equates to a lot of money to alot of people for a lot of crap that they want to throw our way!! And where will they be if we don't need it??

Global Multiple Sclerosis Market will expand steadily from 2009 to 2024 - new report explains
The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those revenues will exceed $9bn during the second half of next decade, our new study shows. The World Health Organization estimates that over 2.5 million people suffer from multiple sclerosis worldwide. The prevalence and onset of MS in children and adults is expected to rise steadily. Global sales for MS therapies will rise accordingly, due to epidemiological, healthcare and commercial drivers.

Heres the link to the article:

http://www.pr-inside.com/examine-the-gl ... 213395.htm

Later, Lora

Lora, this sounds like MS research is some kind of matrix of commerce and people with MS are it's inhabitants.

Yeah, it kind of makes the hair go up and the skin crawl, don't it....

Facet Biotech Reports Third Quarter 2009 Financial Results

"We expect our lead program, daclizumab in multiple sclerosis, to enter a second registration-enabling study in the first half of 2010, triggering a $30 million milestone payment to us from Biogen Idec.”

Total revenues for the third quarter of 2009 were $10.8 million compared to $5.0 million in the same period of 2008.

In the same vein, here's another link to just how profitable MS'rs are:

http://www.marketwire.com/press-release ... 70378.html

For the new folks on board....Marie was the second patient treated at Stanford. She is getting on with her life, doing really well and not on here as much. I miss her! She updates her recovery in the regimens section.

This post was prescient. Marie knew things at Stanford would not continue on, eventually there would be a clinical trial and the come one, come all procedures would be discontinued. Her argument is a sound one...how can those with stenosis and a proven scientific link to their progressed MS (via the Zamboni research and upcoming Jacobs research) be denied venous treatment? Shouldn't there be compassionate treatment for these folks? We do it with cancer drugs, why not venous intervention?
some food for thought,
cheer

certainly do miss Marie . Her calm and well researched answers were the high standard here at TIMS.




Mr. Success